Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mepolizumab - GlaxoSmithKline

Drug Profile

Mepolizumab - GlaxoSmithKline

Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 01 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University; National Institute of Allergy and Infectious Diseases
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Registered Churg-Strauss syndrome; Hypereosinophilic syndrome
  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Nasal polyps
  • Phase II Eosinophilic oesophagitis
  • Discontinued Atopic dermatitis

Most Recent Events

  • 01 Oct 2020 Discontinued - Phase-I/II for Eosinophilic oesophagitis (In adolescents, In children) in Australia, Canada, USA, United Kingdom (IV), before October 2020 (GlaxoSmithKline pipeline, October 2020)
  • 01 Oct 2020 Discontinued - Phase-I/II for Eosinophilic oesophagitis in Switzerland (IV), before October 2020 (GlaxoSmithKline pipeline, October 2020)
  • 01 Oct 2020 Discontinued - Phase-II for Atopic dermatitis (In the elderly, In adults) in Canada, USA (SC), before October 2020 (GlaxoSmithKline pipeline, October 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top